Group 1 - The core viewpoint of the article highlights significant financial projections and strategic developments within the biopharmaceutical industry, particularly focusing on companies like Shengnuo Bio, Shanghai Laishi, and Beijing Saiseng Pharmaceutical [1] Group 2 - Shengnuo Bio anticipates a substantial increase in net profit for the first half of 2025, projecting between 77.03 million to 94.14 million yuan, representing a year-on-year increase of 253.54% to 332.10% [1] - Shanghai Laishi has announced a 4.2 billion yuan acquisition of 100% equity in Nanyue Bio, with potential additional payments based on the company's plasma collection volume, indicating a strategic move to enhance its "plasma" strategy [1] - Beijing Saiseng Pharmaceutical signed a technology transfer contract with its affiliate, Beijing BGI Protein Research Center, for the NeoAB33 new drug project, which may optimize asset structure and support further R&D funding [1] Group 3 - The CDE has accepted the application for the new indication of Eli Lilly's Pirtobrutinib tablets, which is expected to strengthen its market position in the treatment of B-cell malignancies [1] - Innovent Biologics' CLDN-18.2 ADC product IBI343 is proposed to be included as a breakthrough therapy for advanced or metastatic pancreatic cancer, marking a significant advancement in treatment options for this indication [1]

｜2025年6月20日 星期五｜ NO.1 圣诺生物上半年归母净利润预增253.54%至332.10% 6月19日晚间，圣诺生物发布公告称，经财务部门初步测算，预计2025年半年度实现归属于母公司所有 者的净利润7702.75万元至9414.48万元，与上年同期相比，增加5523.99万元至7235.71万元，同比增加 253.54%至332.10%。 每经记者｜陈星 每经编辑｜张益铭 北京赛升药业股份有限公司与参股公司北京华大蛋白质研发中心有限公司签署《新药技术转让合同》， 华大蛋白将其拥有的NeoAB33新药项目相关技术转让给公司，交易总额为2000万元。 点评：华大蛋白2024年亏损830万元，此次转让或优化其资产结构。而赛升药业2025年一季度净利润达 3997万元，具备资金实力推进研发。 NO.4 礼来可逆BTK抑制剂新适应证国内申报上市 CDE官网显示，礼来匹妥布替尼片新适应证上市申请获受理。根据临床试验进展，Insight数据库推测该 药物用于治疗既往接受过BTK抑制剂（布鲁顿氏酪氨酸激酶）治疗的慢性淋巴细胞白血病/小淋巴细胞 淋巴瘤。 点评：匹妥布替尼是全球首个非共价BTK抑制剂，为共价BTK ...

4月29日4时10分，我国在文昌航天发射场使用长征五号乙运载火箭/远征二号上面级，成功将卫星互联 网低轨03组卫星发射升空，卫星顺利进入预定轨道，发射任务获得圆满成功。截至目前，我国建设的低 轨卫星星座——千帆星座已完成五个批次的组网卫星发射，全面进入常态化发射组网阶段。千帆星座计 划的核心卫星制造承载单位格思航天2022年协同联合体取得千帆星座超600颗组网卫星订单，订单额约 45亿元人民币，并已成功发射两批次共计36颗卫星，近期将发射第三批次18颗卫星，2025年预计将完成 超200颗千帆星座一代卫星交付。 【大势展望】 苹果美股盘后一度跌超4% 隔夜美股截至收盘，道琼斯工业平均指数比前一交易日上涨83.60点，收于40752.96点，涨幅为0.21%； 标准普尔500种股票指数上涨35.08点，收于5604.14点，涨幅为0.63%；纳斯达克综合指数上涨264.40 点，收于17710.74点，涨幅为1.52%。大型科技股多数上涨，微软大涨超7%，Meta涨超4%，亚马逊美 股盘后一度跌超5%。苹果美股盘后一度跌超4%。 热门中概股涨跌不一，纳斯达克中国金龙指数涨0.22%。瑞幸咖啡涨超4%，霸王茶姬涨 ...